SENSORION overview

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced it will host a webconference for its retail shareholders on April 7, 2025, following its Full-Year 2024 release. The webconference will be held in French. Sensorion’s Chief Executive Officer, Nawal Ouzren, and management team, will host a webconference dedicated to its...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation at the Van Lanschot Kempen conference , to be held in Amsterdam, Netherlands, on April 2-3, 2025. This conference is an important meeting place for life sciences companies and institutional investors. Sensorion's management team will be present for...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2024 results, provided a corporate update, and announced the availability of the full-year report. “This past year has been an exceptional period of progress on clinical and corporate development fronts,” commented Nawal Ouzren, Chief Executive Officer of...

Regulatory News: Sensorion (FR0012596468 - ALSEN) , a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the enrollment of the last patient in its NOTOXIS Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for the prevention of Cisplatin-Induced Ototoxicity (CIO). The NOTOXIS trial (ClinicalTrials.gov ID: NCT05628233) evaluates the efficacy of SENS-401 in preventing CIO...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Data Monitoring Committee (DMC) recommended the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, the Company’s gene therapy program being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene....

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation in upcoming investor conferences taking place throughout March. Nawal Ouzren, Chief Executive Officer, and Laurene Danon, Chief Financial Officer, will participate in Cowen’s 45 th Annual Health Care Conference , which will be held in Boston, USA, on...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation in upcoming congresses in March. Christine Le Bec, PhD, Head of Analytical Development & QC, will participate in the Innovative Biologics and CMC Challenges vol.2 event, which will take place in Charleroi, Belgium, on March 11-12, 2025 On this occasion,...